Companies

Indivior Plc

NASDAQ: INDV

24/7 Wall St. View

About Indivior

Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) is a specialty pharmaceutical company focused on treating opioid use disorder (OUD), which it describes as a chronic but treatable brain disease.

Its core product is SUBLOCADE, a long-acting injectable buprenorphine treatment. SUBLOCADE generated the large majority of the company's net revenue, and more than 583,000 U.S. patients have been prescribed it since launch. The company also sells sublingual buprenorphine and other legacy addiction-treatment products in the U.S. and in Rest of World markets.

It has discontinued promotional support for PERSERIS (a long-acting injectable risperidone for schizophrenia) and OPVEE (nalmefene nasal spray for opioid overdose).

In August 2026, Indivior agreed to an all-stock merger of equals with Supernus Pharmaceuticals to create a diversified, CNS-focused biopharmaceutical company. Shareholders approved the deal in October 2026. It is expected to close on November 2, 2026, after which the combined company will operate as Supernus, Inc. and trade on Nasdaq under the ticker SUPN. Updated

Latest Activity

INDVIndivior
Q3 2026
EPS
$1.32
est $1.12+18.0%
Revenue
$356M
est $329M+8.1%

This is the last quarter Indivior reports as a standalone company, and it went out with a fifth straight EPS beat, again exceeding expectations. The Supernus merger closes November 2, with shares trading under the new symbol the next day.

Quarterly EPS — reported vs estimate

INDV Coverage

Frequently Asked Questions

What does Indivior do?

Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) is a specialty pharmaceutical company focused on treating opioid use disorder (OUD), which it describes as a chronic but treatable brain disease. Its core product is SUBLOCADE, a long-acting injectable buprenorphine treatment.